Observational studyJapanese journal of clinical oncology2025
Real-world safety and effectiveness of alemtuzumab for relapsed or refractory chronic lymphocytic leukaemia: results from postmarketing surveillance in Japan.
Observational study in Japanese journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundAlemtuzumab is a monoclonal antibody directed against CD52 on T and B lymphocytes and is used to treat lymphoproliferative disorders including chronic lymphocytic leukaemia (CLL). This postmarketing surveillance, as mandated by the Japanese health authorities, investigated the safety and effectiveness of alemtuzumab in Japanese patients receiving alemtuzumab for relapsed/refractory CLL.
methodsThis was an observational, prospective study conducted in patients with lymphoproliferative disorders who received alemtuzumab in routine clinical practice in Japan between March 2015 and June 2023. Follow-up was for 24 weeks after alemtuzumab administration. Endpoints were adverse drug reactions (ADRs), objective response rate (ORR), progression-free survival (PFS) and overall survival (OS), and factors associated with safety and effectiveness.
resultsSafety was evaluated in 179 patients with lymphoproliferative disorders (112 males and 67 females; median age 68 years) and effectiveness in 95 with relapsed/refractory CLL. Overall, 138 patients (77.1%) developed an ADR (most commonly cytomegalovirus [CMV]-related events [37.4%]), 100 (55.9%) developed serious ADRs (most commonly CMV-related events [31.3%]), and 93 (52.0%) developed grade ≥ 3 ADRs (most commonly decreased platelet count [13.4%]). Of 95 patients with relapsed/refractory CLL, 39 (41.1%) had an ORR (15 complete and 24 partial responses). At 24 weeks, PFS and OS rates were 55.5% and 70.0%, respectively. The ORR was significantly associated with Rai classification, performance status, and treatment days or duration.
conclusionsThis prospective postmarketing surveillance study confirms the effectiveness and manageable safety profile of alemtuzumab for Japanese patients with relapsed/refractory CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.